These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6843182)

  • 21. Long-term blood pressure control with pindolol given once daily.
    Frithz G; Danielson M; Henningsen N; Malmborg RO; Nordström-Ohrberg G; Schröder G
    Eur J Cardiol; 1978; 7(2-3):131-6. PubMed ID: 27369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the beta-receptor blocking agent visken on blood pressure of hypertensive patients, on plasma renin activity and electrolytes.
    Sonkodi S; Pap A; Varró V
    Ther Hung; 1976; 24(2):60-2. PubMed ID: 982340
    [No Abstract]   [Full Text] [Related]  

  • 23. [The influence of the beta-blocking agent pindolol on blood pressure and heart weight of rats with Goldblatt-type hypertension (author's transl)].
    Girndt J; Kramer A; Scheler F
    Klin Wochenschr; 1977 Apr; 55(7):349-50. PubMed ID: 140270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure reactivity in the evaluation of resting blood pressure and mood responses to pindolol and propranolol in hypertensive patients.
    Potempa KM; Fogg LF; Fish AF; Kravitz HM
    Heart Lung; 1993; 22(5):383-91. PubMed ID: 8226001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive effect of bopindolol: a multi-centre study.
    Török E; Szám I; Buday G; Kerkovits G; Farsang C; Hajtman B
    J Hum Hypertens; 1990 Aug; 4(4):458-60. PubMed ID: 1979635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of pindolol for treatment of neurocardiogenic syncope.
    Nair N; Padder FA; Kutalek SP; Kantharia BK
    Am J Cardiol; 2004 Nov; 94(9):1189-91. PubMed ID: 15518620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decrease in beta-receptor density explaining the development of pindolol- and prenalterol-tolerance in orthostatic hypotension.
    Andersen EB; Lindskov HO; Marving J; Boesen F; Beck-Nielsen H; Hesse B
    Dan Med Bull; 1985 Jun; 32(3):194-6. PubMed ID: 2861975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct 24-hour haemodynamic monitoring after starting beta-blocker therapy: studies with pindolol in hypertension.
    v d Meiracker A; Man in't Veld AJ; van Eck HR; Wenting GJ; Schalekamp MA
    J Hypertens Suppl; 1984 Dec; 2(3):S581-3. PubMed ID: 6100755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension.
    Sasaki J; Saku K; Ideishi M; Arakawa K; Kato Y; Kuwano E; So T
    Clin Ther; 1989; 11(2):219-24. PubMed ID: 2736568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pindolol: a potent beta-adrenergic blocking agent in the treatment of hypertension.
    Jaroonvesma N; Charoenlarp K
    J Int Med Res; 1978; 6(6):435-40. PubMed ID: 363480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Essential arterial hypertension. Antihypertensive effect of the beta adrenergic blockader pindolol].
    Torres Zamora M
    Prensa Med Mex; 1977; 42(3-4):127-32. PubMed ID: 917991
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of Visken-15 for treating hypertension].
    Erina EV; Megrelishvili RI; Pushkar' IuT; Beliakova EV; Lediashova GA
    Kardiologiia; 1979 Mar; 19(3):46-52. PubMed ID: 372668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacology of adrenergic-adrenoreceptor-blocking drugs.
    Louis WJ; Taylor H; McNeil JJ; Jarrott B; Rand MJ
    Am Heart J; 1982 Aug; 104(2 Pt 2):407-12. PubMed ID: 6125097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adrenergic beta receptor blockaders with intrinsic sympathomimetic activity in the treatment of arterial hypertension].
    Pyda M; Grajek S
    Kardiol Pol; 1988; 31(4):261-70. PubMed ID: 2906104
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience with pindolol, a betareceptor blocker, in the treatment of hypertension.
    Atterhög JH; Dunér H; Pernow B
    Am J Med; 1976 May; 60(6):872-6. PubMed ID: 14501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hypertension with a new beta-blocking agent, pindolol (Visken).
    Persson I; Ulrich J
    Eur J Clin Pharmacol; 1973 Dec; 6(4):217-9. PubMed ID: 4591149
    [No Abstract]   [Full Text] [Related]  

  • 37. Intrinsic sympathomimetic activity and the effects of beta-adrenergic blocking drugs on vulnerability to ventricular fibrillation.
    Raeder EA; Verrier RL; Lown B
    J Am Coll Cardiol; 1983 Jun; 1(6):1442-6. PubMed ID: 6133890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methyldopa combined with prindolol in the treatment of severe hypertension.
    Seedat YK
    S Afr Med J; 1974 Aug; 48(38):1608-10. PubMed ID: 4615382
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients.
    Lancaster R; Goodwin TJ; Peart WS
    Br J Clin Pharmacol; 1976 Jun; 3(3):453-60. PubMed ID: 973972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in depressed cardiac function in hypertensive patients during pindolol treatment.
    Plotnick GD; Fisher ML; Wohl B; Hamilton JH; Hamilton BP
    Am J Med; 1984 Jan; 76(1):25-30. PubMed ID: 6691357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.